

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BORMAN ET AL.

Atty. Ref.: 620-442

Serial No. 10/583,896

Group: Unknown

Filed: June 22, 2006

Examiner: Unknown

For: EP2 RECEPTOR AGONISTS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 3, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-442

10/583,896

APPLICANT

BORMAN ET AL.

(Use several sheets if necessary)

FILING DATE

GROUP

June 22, 2006

Unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,562,868	05/2003	Stjerschantz et al			
	6,235,781	05/2001	Weiner et al			
	6,011,062	01/2000	Schneider et al			
	6,090,847	07/2000	Woodward			
	5,889,052	03/1999	Klimko et al			
	5,877,211	03/1999	Woodward			
	5,849,792	12/1998	Schneider			
	5,698,598	12/1997	Woodward			
	5,631,287	05/1997	Schneider			
	5,576,347	11/1996	Sredni et al			
	5,462,968	10/1995	Woodward			
	4,599,353	07/1986	Bito			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 03/040126	05/2003	WIPO			
WO 03/037433	05/2003	WIPO			
WO 02/24647	03/2002	WIPO			
WO 01/46140	06/2001	WIPO			
WO 00/40248	07/2000	WIPO			
WO 00/31084	06/2000	WIPO			
WO 99/26629	06/1999	WIPO			
WO 98/34916	08/1998	WIPO			
WO 98/27976	07/1998	WIPO			
WO 95/19964	07/1995	WIPO			
GB 2 293 101	03/1996	United Kingdom			
EP 0 789 687	12/2001	Europe			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Bagli, J. et al., <i>J. Org. Chem.</i> , 1972 , 37, 2132-2138
	Berge, et al., <i>J. Pharm. Sci.</i> , 66 , 1-19 (1977)
	Bernady, K.F., <i>J. Org. Chem.</i> , 1980 45, 4702-4715
	Breyer, R.M., et al., <i>Ann. N.Y. Acad. Sci.</i> , 905 , 221-231 (2000)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A826 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-442

10/583,896

APPLICANT

BORMAN ET AL.

(Use several sheets if necessary)

FILING DATE

GROUP

June 22, 2006

Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

<input type="checkbox"/>	Brown, H.C., <i>et al.</i> <i>J. Am. Chem. Soc.</i> , 110 , 1539-1546 (1988)
<input type="checkbox"/>	Chen, J., <i>et al.</i> , <i>Invest. Ophthalmol. Visual Sci.</i> , 32(4) , 870 (1991)
<input type="checkbox"/>	Funk, R.L., <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 115 , 8849-8850 (1993)
<input type="checkbox"/>	Griffiths, C., <i>Current Drugs Targets – Inflammation & Allergy</i> , 3 , 157-161, (2004)
<input type="checkbox"/>	Hamann, P.R. and Wissner, A., <i>Syn.Comms.</i> , 19 , 1509-1518 (1989)
<input type="checkbox"/>	Hayashi, T., <i>Synlett</i> , SI , 879-887 (2001)
<input type="checkbox"/>	Hayashi, T., <i>et al.</i> , <i>JACS</i> , 124 , 12102-12103 (2002)
<input type="checkbox"/>	Hillock, C.J. and Crankshaw, D.J., <i>European Journal of Pharmacology</i> , 378 , 99-108 (1999)
<input type="checkbox"/>	Huckin, S.N. and Weiler, L., <i>Can.J.Chem.</i> , 52 , 2157 (1974)
<input type="checkbox"/>	Jozefowski, S. <i>et al</i> <i>Int. Immun.</i> , 3 865 - 878 (2003)
<input type="checkbox"/>	Kanda N., <i>et al.</i> , <i>J Allergy Clin. Immunol.</i> , 114 , (No 6), (1403 - 1409)
<input type="checkbox"/>	Lebwohl, M., <i>Lancet</i> , 361 , 1197-1204 (2003)
<input type="checkbox"/>	Nials, A.T., <i>et al.</i> , <i>Cardiovascular Drug Reviews</i> , 11(2) , 165-179 (1993)
<input type="checkbox"/>	Nataraj, C., <i>et al.</i> , <i>J. Clinical Investigation</i> , 108 , (No 8), 1229 - 1235 (2001)
<input type="checkbox"/>	Patterson, J.W., <i>et al.</i> , <i>Synthesis</i> , 1985, 337-338
<input type="checkbox"/>	Paralkar, V.M., <i>et al.</i> , <i>PNAS</i> , 100(11) , 6736-6740 (2003)
<input type="checkbox"/>	Salim, A. & Emerson, R., <i>Curr. Opin. Investig. Drugs</i> , 2(11) , 1546-8 (2001)
<input type="checkbox"/>	Suzuki, M., <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 107 , 3348-3349 (1985)
<input type="checkbox"/>	Taber, D.F., <i>et al.</i> , <i>J. Org. Chem.</i> , 62 , 194-198 (1997)
<input type="checkbox"/>	Takaya, Y., <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 120 , 5579-5580 (1998)
<input type="checkbox"/>	Thompson, W.J. and Gaudino, J., <i>J. Org. Chem.</i> , 49 , 5237-5243 (1984)
<input type="checkbox"/>	Urban, E., <i>et al.</i> , <i>Tetrahedron</i> , 52 , 971-986 (1996)
<input type="checkbox"/>	Vancheri, C., <i>et al</i> <i>Trends in Immunology</i> , 25 (No 1) 40 - 46 (2004)
<input type="checkbox"/>	Weiler, L., <i>J. Am. Chem. Soc.</i> , 92 , 6702-6704 (1970)
<input type="checkbox"/>	Woodward, D.F., <i>et al.</i> , <i>Invest. Ophthalmol. Visual Sci.</i> , 32(4) , 1257 (1991)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 600; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-AIE20 (Also PTO-1449)